Chaitanya Iragavarapu — University of Kentucky

If you made any changes in Pure these will be visible here soon.

Education/Academic qualification

Post Doctoral Fellow, Stanford University

2019

Post Doctoral Fellow, New York Medical College

2018

Residency, New York Medical College

2015

Bachelor of Medicine, Bachelor of Surgery, Other Institution

2011

3 Finished
6 Active

23-NHL-29-DO: MK2140-003, A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)
Iragavarapu, C.
Merck Sharp & Dohme Corporation
6/26/23 → 6/26/25
Project: Research project
22-NHL-28-KP-PMC: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma, ZUMA-22
Iragavarapu, C.
Kite Pharma Incorporated
3/6/23 → 12/5/23
Project: Research project
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Iragavarapu, C. & Hildebrandt, G.
Genmab US Incorporated
12/15/21 → 7/31/24
Project: Research project
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus RCHOP in Previously Untreated, High-intermediate
Iragavarapu, C.
MorphoSys AG
9/29/21 → 8/21/24
Project: Research project
Expanded Access Protocol (EAP) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming For Commercial Release
Iragavarapu, C.
Celgene
4/6/21 → 3/15/24
Project: Research project